-
Algorithm for Rapid Exclusion of Clinically Relevant Plasma Levels of Direct Oral Anticoagulants in Patients Using the DOAC Dipstick: An Expert Consensus Paper Thromb. Haemost. (IF 6.7) Pub Date : 2024-03-08 Job Harenberg, Robert C. Gosselin, Adam Cuker, Cecilia Becattini, Ingrid Pabinger, Sven Poli, Jeffrey Weitz, Walter Ageno, Rupert Bauersachs, Ivana Celap, Philip Choi, James Douketis, Jonathan Douxfils, Ismail Elalamy, Anna Falanga, Jawed Fareed, Emmanuel J. Favaloro, Grigorios Gerotziafas, Harald Herkner, Svetlana Hetjens, Lars Heubner, Robert Klamroth, Forian Langer, Gregory Y. H. Lip, Brian Mac
Background With the widespread use of direct oral anticoagulants (DOACs), there is an urgent need for a rapid assay to exclude clinically relevant plasma levels. Accurate and rapid determination of DOAC levels would guide medical decision-making to (1) determine the potential contribution of the DOAC to spontaneous or trauma-induced hemorrhage; (2) identify appropriate candidates for reversal, or (3)
-
Racial Differences in Bleeding Risk: An Ecological Epidemiological Study Comparing Korea and United Kingdom Subjects Thromb. Haemost. (IF 6.7) Pub Date : 2024-03-08 Dong-Seon Kang, Pil-Sung Yang, Daehoon Kim, Eunsun Jang, Hee Tae Yu, Tae-Hoon Kim, Jung Hoon Sung, Hui-Nam Pak, Moon-Hyoung Lee, Gregory Y.H. Lip, Boyoung Joung
Background This study aimed to evaluate racial differences in bleeding incidence by conducting an ecological epidemiological study using data from Korea and the United Kingdom. Methods We included healthy participants from the Korean National Health Insurance Service-Health Screening and the UK Biobank who underwent health examinations between 2006 and 2010 and had no comorbidities or history of medication
-
ADAMTS13 or Caplacizumab Reduces the Accumulation of Neutrophil Extracellular Traps and Thrombus in Whole Blood of COVID-19 Patients under Flow Thromb. Haemost. (IF 6.7) Pub Date : 2024-03-05
Background Neutrophil NETosis and neutrophil extracellular traps (NETs) play a critical role in pathogenesis of coronavirus disease 2019 (COVID-19)-associated thrombosis. However, the extents and reserve of NETosis, and potential of thrombus formation under shear in whole blood of patients with COVID-19 are not fully elucidated. Neither has the role of recombinant ADAMTS13 or caplacizumab on the accumulation
-
Causal Effects of COVID-19 on the Risk of Thrombosis: A Two-Sample Mendel Randomization Study Thromb. Haemost. (IF 6.7) Pub Date : 2024-03-05 Zhengran Li, Minghui Zeng, Tong Wu, Zijin Wang, Yuxin Sun, Ziran Zhang, Fanye Wu, Zejun Chen, Min Fu, Fanke Meng
Background Coronavirus disease 2019 (COVID-19) and thrombosis are linked, but the biomolecular mechanism is unclear. We aimed to investigate the causal relationship between COVID-19 and thrombotic biomarkers. Methods We used two-sample Mendelian randomization (MR) to assess the effect of COVID-19 on 20 thrombotic biomarkers. We estimated causality using inverse variance weighting with multiplicative
-
No Genetic Causality between Tobacco Smoking and Venous Thromboembolism: A Two-Sample Mendelian Randomization Study Thromb. Haemost. (IF 6.7) Pub Date : 2024-02-22
Background Given the current debate in clinical research about the relationship between tobacco smoking and the risk of venous thromboembolism (VTE), a Mendelian randomization (MR) study was conducted aimed at elucidating the causal associations of current and past tobacco smoking with the risk of VTE, from the perspective of genetics. Methods Two-sample univariate and multivariable MR analyses were
-
Glycosaminoglycans: Participants in Microvascular Coagulation of Sepsis Thromb. Haemost. (IF 6.7) Pub Date : 2024-02-15 Nanxi Li, Ruolin Hao, Peng Ren, Jingya Wang, Jiahui Dong, Tong Ye, Danyang Zhao, Xuan Qiao, Zhiyun Meng, Hui Gan, Shuchen Liu, Yunbo Sun, Guifang Dou, Ruolan Gu
Sepsis represents a syndromic response to infection and frequently acts as a common pathway leading to fatality in the context of various infectious diseases globally. The pathology of severe sepsis is marked by an excess of inflammation and activated coagulation. A substantial contributor to mortality in sepsis patients is widespread microvascular thrombosis-induced organ dysfunction. Multiple lines
-
Icaritin Sensitizes Thrombin- and TxA2-Induced Platelet Activation and Promotes Hemostasis via Enhancing PLCγ2-PKC Signaling Pathways Thromb. Haemost. (IF 6.7) Pub Date : 2024-02-09
Background Vascular injury results in uncontrollable hemorrhage in hemorrhagic diseases and excessive antithrombotic therapy. Safe and efficient hemostatic agents which can be orally administered are urgently needed. Platelets play indispensable roles in hemostasis, but there is no drug exerting hemostatic effects through enhancing platelet function. Methods The regulatory effects of icaritin, a natural
-
Proteomic Characterization of Plasma in Lemierre's Syndrome Thromb. Haemost. (IF 6.7) Pub Date : 2024-02-07 David Nygren, Gustav Torisson, Lotta Happonen, Lisa Mellhammar, Adam Linder, Johan Elf, Hong Yan, Charlotte Welinder, Karin Holm
Background The underlying mechanisms of thrombosis in Lemierre's syndrome and other septic thrombophlebitis are incompletely understood. Therefore, in this case control study we aimed to generate hypotheses on its pathogenesis by studying the plasma proteome in patients with these conditions. Methods All patients with Lemierre's syndrome in the Skåne Region, Sweden, were enrolled prospectively during
-
DNMT3A/TET2/ASXL1 Mutations are an Age-independent Thrombotic Risk Factor in Polycythemia Vera Patients: An Observational Study Thromb. Haemost. (IF 6.7) Pub Date : 2024-01-30
Background Polycythemia vera (PV) patients are classified as high or low thrombotic risk based on age and prior history of thrombosis. Despite adherence to treatment recommendations, vascular events remain frequent, leading us to question whether thrombotic risk stratification could be improved. We previously reported an association between thrombotic events and mutations in DTA genes (DNMT3A, TET2
-
Risk of Depression after Venous Thromboembolism in Patients with Hematological Cancer: A Population-Based Cohort Study Thromb. Haemost. (IF 6.7) Pub Date : 2024-01-18
Background Venous thromboembolism (VTE) may complicate the clinical course of cancer patients and add to their psychological burden. Objectives We aimed to investigate the association between VTE and risk of subsequent depression in patients with hematological cancer. Patients and Methods We conducted a population-based cohort study using Danish national health registries. Between 1995 and 2020, we
-
Platelet-Derived TGF-β1 Promotes Deep Vein Thrombosis Thromb. Haemost. (IF 6.7) Pub Date : 2024-01-15
Background Transforming growth factor-β1 (TGF-β1) modulates multiple cellular functions during development and tissue homeostasis. A large amount of TGF-β1 is stored in platelet α-granules and released upon platelet activation. Whether platelet-derived TGF-β1 plays a role in venous thrombosis remains unclear. This study intends to assess the role of platelet-derived TGF-β1 in the development of venous
-
Percutaneous Coronary Intervention in Acute Coronary Syndrome with Mild-to-Moderate Thrombocytopenia Thromb. Haemost. (IF 6.7) Pub Date : 2024-01-10 Yicong Ye, Yongchen Hao, Xiliang Zhao, Jun Liu, Na Yang, Sidney C. Smith Jr, Yong Huo, Gregg C. Fonarow, Junbo Ge, Louise Morgan, Zhaoqing Sun, Danqing Hu, Yiqian Yang, Chang-Sheng Ma, Dong Zhao, Yaling Han, Jing Liu, Yong Zeng
Background Baseline thrombocytopenia is commonly observed in patients with acute coronary syndrome (ACS) requiring percutaneous coronary intervention (PCI). Aim The purpose of this analysis was to investigate safety and effectiveness of PCI in ACS patients with baseline mild-to-moderate thrombocytopenia. Methods The data were collected from the Improving Care for Cardiovascular Disease in China–Acute
-
The Effect of Cytokine Adsorption on Leukocyte and Platelet Activation after Extracorporeal Cardiopulmonary Resuscitation Thromb. Haemost. (IF 6.7) Pub Date : 2024-01-10 Timm Zahn, Nancy Schanze, Dawid L. Staudacher, Tobias Wengenmayer, Sven Maier, Christoph Benk, Nadine Gauchel, Daniel Duerschmied, Alexander Supady
Background Post-cardiac arrest syndrome (PCAS) is a frequent complication following successful cardiopulmonary resuscitation and correlates with poor outcome. PCAS is characterized by an excessive inflammatory response to whole-body ischemia and reperfusion. Cytokine adsorption was suggested as an adjunctive treatment option for the removal of cytokines from the patients' blood to restore the physiological
-
Early Time Courses of Recurrent Venous Thromboembolism and Bleeding during Apixaban or Dalteparin Therapy for Patients with Cancer Thromb. Haemost. (IF 6.7) Pub Date : 2024-01-09 Alexander T. Cohen, Katherine J. Creeper, Raza Alikhan, Chaozer Er, Jean M. Connors, Menno V. Huisman, Andres Munoz, Giorgio Vescovo, Rupert Bauersachs, Walter Ageno, Giancarlo Agnelli, Cecilia Becattini
Background In patients with acute venous thromboembolism (VTE), the rates of recurrence and major bleeding are highest during the first weeks of anticoagulation. The CARAVAGGIO trial demonstrated noninferiority of apixaban to dalteparin for treatment of cancer-associated VTE without an increased risk of major bleeding. We compared the early time course of VTE recurrence and major bleeding events of
-
Identification of Factor XIII β-Sandwich Residues Mediating Glutamine Substrate Binding and Activation Peptide Cleavage Thromb. Haemost. (IF 6.7) Pub Date : 2024-01-09
Background Factor XIII (FXIII) forms covalent crosslinks across plasma and cellular substrates and has roles in hemostasis, wound healing, and bone metabolism. FXIII activity is implicated in venous thromboembolism (VTE) and is a target for developing pharmaceuticals, which requires understanding FXIII – substrate interactions. Previous studies proposed the β-sandwich domain of the FXIII A subunit
-
Diphenyl-tetrazol-propanamide Derivatives Act as Dual-Specific Antagonists of Platelet CLEC-2 and Glycoprotein VI Thromb. Haemost. (IF 6.7) Pub Date : 2023-12-29 Nobuo Watanabe, Yoshiko Shinozaki, Sanae Ogiwara, Riko Miyagasako, Ayumi Sasaki, Junko Kato, Yusuke Suzuki, Natsuko Fukunishi, Yoshinori Okada, Takeshi Saito, Yumi Iida, Misaki Higashiseto, Haruchika Masuda, Eiichiro Nagata, Kazuhito Gotoh, Mari Amino, Tomoatsu Tsuji, Seiji Morita, Yoshihide Nakagawa, Noriaki Hirayama, Sadaki Inokuchi
Background Platelet C-type lectin-like receptor 2 (CLEC-2) induces platelet activation and aggregation after clustering by its ligand podoplanin (PDPN). PDPN, which is not normally expressed in cells in contact with blood flow, is induced in inflammatory immune cells and some malignant tumor cells, thereby increasing the risk of venous thromboembolism (VTE) and tumor metastasis. Therefore, small-molecule
-
Ethnic Differences in Thrombotic Profiles of Acute Coronary Syndrome Patients and Relationship to Cardiovascular Outcomes: A Comparison of East Asian and White subjects Thromb. Haemost. (IF 6.7) Pub Date : 2023-12-29 Jung-Won Suh, Vassilios Memtsas, Ying X Gue, Hyoung-Won Cho, Wonjae Lee, Si-Hyuck Kang, Diana A. Gorog
Background East Asians (EAs), compared to white Caucasians (W), have a lower risk of ischemic heart disease and a higher risk of bleeding with antithrombotic medications. The underlying mechanisms are incompletely understood. Objectives We sought to compare thrombotic profiles of EA and W patients with myocardial infarction (MI) and relate these to cardiovascular outcomes. Methods In a prospective
-
Outcomes of Patients with a Mechanical Heart Valve and Poor Anticoagulation Control on Warfarin Thromb. Haemost. (IF 6.7) Pub Date : 2023-12-29
Background Patients with a mechanical heart valve (MHV) require oral anticoagulation. Poor anticoagulation control is thought to be associated with adverse outcomes, but data are limited. Objective To assess the risks of clinical outcomes in patients with a MHV and poor anticoagulation control on warfarin. Patients/Methods We conducted a retrospective study of consecutive patients undergoing MHV implantation
-
Gaining Insights into Inherited Bleeding Disorders of Complex Etiology in Pediatric Patients: Whole-Exome Sequencing as First-Line Investigation Tool Thromb. Haemost. (IF 6.7) Pub Date : 2023-12-29 Perla Bandini, Nina Borràs, Ruben Berrueco, Susanna Gassiot, Laura Martin-Fernandez, Edurne Sarrate, Natàlia Comes, Lorena Ramírez, Carlos Hobeich, Francisco Vidal, Irene Corrales
Introduction Investigation of the molecular basis of inherited bleeding disorders (IBD) is mostly performed with gene panel sequencing. However, the continuous discovery of new related genes underlies the limitation of this approach. This study aimed to identify genetic variants responsible for IBD in pediatric patients using whole-exome sequencing (WES), and to provide a detailed description and reclassification
-
Association and Pathways between Dietary Manganese Intake and Incident Venous Thromboembolism Thromb. Haemost. (IF 6.7) Pub Date : 2023-12-27 Yu Huang, Yanjun Zhang, Sisi Yang, Hao Xiang, Chun Zhou, Ziliang Ye, Mengyi Liu, Panpan He, Yuanyuan Zhang, Xiaoqin Gan, Xianhui Qin
Background The association between dietary manganese (Mn) intake and the risk of venous thromboembolism (VTE) remains unknown. We aimed to investigate the associations of dietary Mn intake with incident VTE, and the underlying mediating roles of obesity markers (body mass index [BMI] and waist circumference), hemorheological parameters (red cell distribution width [RDW], platelet count [PLT], and mean
-
Cost-Effectiveness of Performing Reference Ultrasonography in Patients with Deep Vein Thrombosis Thromb. Haemost. (IF 6.7) Pub Date : 2023-12-27
Background The diagnosis of recurrent ipsilateral deep vein thrombosis (DVT) with compression ultrasonography (CUS) may be hindered by residual intravascular obstruction after previous DVT. A reference CUS, an additional ultrasound performed at anticoagulant discontinuation, may improve the diagnostic work-up of suspected recurrent ipsilateral DVT by providing baseline images for future comparison
-
Complete F9 Gene Deletion, Duplication, and Triplication Rearrangements: Implications for Factor IX Expression and Clinical Phenotypes Thromb. Haemost. (IF 6.7) Pub Date : 2023-12-26
Background Factor IX (FIX) plays a critical role in blood coagulation. Complete deletion of F9 results in severe hemophilia B, whereas the clinical implications of complete F9 duplication and triplication remain understudied. Objective To investigate the rearrangement mechanisms underlying complete F9 deletion (cases 1 and 2), duplication (cases 3 and 4), and triplication (case 5), and to explore their
-
Antithrombotic Prophylaxis with Rivaroxaban in Patients with Prehospital COVID-19: A Meta-analysis of Two Placebo-Controlled Trials Thromb. Haemost. (IF 6.7) Pub Date : 2023-12-21 Judith Hsia, Alex C. Spyropoulos, Gregory Piazza, Stephen Weng, Michael W. Dunne, Concetta Lipardi, Elliot S. Barnathan, Marc P. Bonaca
Background We conducted a prespecified meta-analysis of two randomized, placebo-controlled trials of rivaroxaban 10 mg daily in prehospital patients with acute coronavirus disease 2019 (COVID-19). Individually, the trials had limited power to detect a treatment effect due to recruitment stopping ahead of plan. Material and Methods The statistical analysis plan for the meta-analysis was finalized before
-
Circulating Cytokines and Venous Thromboembolism: A Bidirectional Two-Sample Mendelian Randomization Study Thromb. Haemost. (IF 6.7) Pub Date : 2023-12-18 Teng Hu, Pengpeng Su, Fangkun Yang, Jiajun Ying, Yu Chen, Hanbin Cui
Background Epidemiological evidence has linked circulating cytokines to venous thromboembolism (VTE). However, it remains uncertain whether these associations are causal due to confounding factors or reverse causality. We aim to explore the causality between circulating cytokines and VTE, encompassing deep vein thrombosis (DVT) and pulmonary embolism (PE). Methods In the current bidirectional Mendelian
-
Thrombosis and Bleeding in Patients with Vaccine-Induced Immune Thrombotic Thrombocytopenia: A Systematic Review of Published Cases Thromb. Haemost. (IF 6.7) Pub Date : 2023-12-18
Introduction Vaccine-induced immune thrombotic thrombocytopenia (VITT) is a highly prothrombotic reaction to COVID-19 (coronavirus disease 2019) adenoviral vector vaccines. Its distinct bleeding and thrombotic patterns compared with other platelet consumptive disorders remain unclear. Methods We performed a systematic review of the literature (PubMed and Embase) up to July 31, 2022, including case
-
Atherosclerotic Autoantigen ALDH4A1 as a Novel Immunological Indicator for Plaque Erosion in Patients with ST Segment Elevated Myocardial Infarction Thromb. Haemost. (IF 6.7) Pub Date : 2023-12-18 Jiannan Li, Runzhen Chen, Jinying Zhou, Ying Wang, Xiaoxiao Zhao, Chen Liu, Peng Zhou, Yi Chen, Li Song, Nan Li, Hongbing Yan, Hanjun Zhao
Objective Aldehyde dehydrogenase 4A1 (ALDH4A1) was recently reported to be a novel autoantigen of atherosclerosis. However, its role in different phenotypes of acute coronary syndrome remains unclear. Herein, we planned to explore the circulating and regional expression of ALDH4A1 in patients with plaque rupture (PR) and plaque erosion (PE) determined by optical coherence tomography (OCT). Methods
-
Ser252Asn Mutation Introduces a New N-Linked Glycosylation Site and Causes Type IIb Protein C Deficiency Thromb. Haemost. (IF 6.7) Pub Date : 2023-11-27 Shijie Zhou, Xi Wu, Ying Song, Lei Li, Chunli Shi, Zhe Lai, Qiulan Ding, Wenman Wu, Jing Dai, Xuefeng Wang, Yeling Lu
Background: Protein C (PC) is a vitamin K-dependent anticoagulant serine protease zymogen which upon activation by the thrombin–thrombomodulin (TM) complex downregulates the coagulation cascade by degrading cofactors Va and VIIIa by limited proteolysis. We identified a thrombosis patient who carried a heterozygous mutation c.881G > A, p.Ser252Asn (S252N) in PROC. This mutation was originally described
-
Persistent and Late-Onset Disseminated Intravascular Coagulation Are Closely Related to Poor Prognosis in Patients with Sepsis Thromb. Haemost. (IF 6.7) Pub Date : 2023-11-21 Tadashi Matsuoka, Kazuma Yamakawa, Toshiaki Iba, Koichiro Homma, Junichi Sasaki
Background Septic-associated disseminated intravascular coagulation (DIC) is heterogeneous regarding prognosis and responsiveness to anticoagulant therapy. Objectives To investigate the relationship between the timing of development and recovery of DIC, its prognosis, and the difference in response to anticoagulant therapy in sepsis-associated DIC patients. Methods This study was performed with a dataset
-
Guided anti-P2Y12 therapy in patients undergoing PCI. Thromb. Haemost. (IF 6.7) Pub Date : 2023-11-22 Marco Cattaneo,Simone Birocchi,Gian Marco Podda,Alessandro Squizzato
not applicable.
-
NOACs in Atrial Fibrillation Patients with Polypharmacy. Thromb. Haemost. (IF 6.7) Pub Date : 2023-11-21 Bernadette Corica,Giulio Francesco Romiti,Marco Proietti
-
Enoxaparin for Long-Term Therapy of Venous Thromboembolism in Patients with Cancer and Renal Insufficiency Thromb. Haemost. (IF 6.7) Pub Date : 2023-11-15 Patricia Sigüenza, Juan J. López-Núñez, Conxita Falgá, Covadonga Gómez-Cuervo, Antoni Riera-Mestre, Aída Gil-Díaz, Peter Verhamme, Ana Cristina Montenegro, Cristina Barbagelata, Egidio Imbalzano, Manuel Monreal, the RIETE Investigators
Background The optimal therapy of venous thromboembolism (VTE) in cancer patients with renal insufficiency (RI) is unknown. Current guidelines recommend to use low-molecular-weight heparin over direct oral anticoagulants to treat VTE in cancer patients at high risk of bleeding. Methods We used the Registro Informatizado Enfermedad Tromboemb00F3lica (RIETE) registry to compare the 6-month incidence
-
COVID-19 and Long-COVID Thrombosis: From Clinical and Basic Science to Therapeutics Thromb. Haemost. (IF 6.7) Pub Date : 2023-11-15
Coronavirus infectious disease-19 (COVID-19) is a pandemic characterized by serious lung disease and thrombotic events in the venous and circulation trees, which represent a harmful clinical sign of poor outcome. Thrombotic events are more frequent in patients with severe disease requiring intensive care units and are associated with platelet and clotting activation. However, after resolution of acute
-
Risk Factors for Bleeding in Cancer Patients Treated with Conventional Dose Followed by Low-Dose Apixaban for Venous Thromboembolism Thromb. Haemost. (IF 6.7) Pub Date : 2023-11-15
Background Incidence of and risk factors for bleeding in cancer patients with venous thromboembolism (VTE) treated with apixaban are poorly described. Methods We analyzed data from the prospective CAP study where 298 cancer patients with any type of VTE received 5 mg apixaban twice daily for 6 months, and then 2.5 mg apixaban twice daily for 30 months. For most analyses, major bleedings and clinically
-
Dual Antiplatelet Therapy or Dual Pathway Inhibition. Thromb. Haemost. (IF 6.7) Pub Date : 2023-11-15 Shinya Goto,Shinichi Goto
-
Obesity and Pulmonary Embolism: Can We Dismantle the "Obesity Paradox". Thromb. Haemost. (IF 6.7) Pub Date : 2023-11-15 Samuel Z Goldhaber
-
Protease-activated receptor-1 IgG autoantibodies in patients with COVID-19. Thromb. Haemost. (IF 6.7) Pub Date : 2023-11-06 Leander Reinshagen,Vanasa Nageswaran,Harald Heidecke,Kai Schulze-Forster,Anne-Christin Beatrice Wilde,Pegah Ramezani Rad,Wolfgang Poller,Erik Asmus,Szandor Simmons,Wolfgang M Kuebler,Martin Witzenrath,Lajos Marko,Kai Jakobs,David M Leistner,Ursula Rauch-Kröhnert,Nicolle Kränkel,Sofia K Forslund,Ulf Landmesser,Dominik N Müller,Arash Haghikia
N/A.
-
Venous Thromboembolism and Estrogen-Containing Gender-Affirming Hormone Therapy Thromb. Haemost. (IF 6.7) Pub Date : 2023-11-02 Caroline Dix, Mollie Moloney, Huyen A. Tran, James D. McFadyen
Gender-affirming therapy involves the use of hormones to develop the physical characteristics of the identified gender and suppressing endogenous sex hormone production. Venous thromboembolism (VTE) is a known risk of exogenous estrogen therapy, and while evidence of VTE risk among transgender women using modern gender-affirming hormone therapy (GAHT) is still emerging, it is thought to affect up to
-
Clinical and Laboratory Presentation and Underlying Mechanism in Patients with Low VWF Thromb. Haemost. (IF 6.7) Pub Date : 2023-11-02
Background Low von Willebrand factor (VWF) refers to subjects with plasma levels of 30 to 50 IU/dL. The mechanism of low VWF is poorly understood. We chose to determine the clinical presentation, laboratory phenotype, and underlying mechanisms of low VWF. Material and Methods We included 250 patients characterized with low VWF. The International Society on Thrombosis and Haemostasis Bleeding Assessment
-
Are NETs a Novel, Exciting, Thrombosis Risk Marker? Thromb. Haemost. (IF 6.7) Pub Date : 2023-11-02 Guozheng Wang,Simon Timothy Abrams,Cheng-Hock Toh
-
Risk of Incident Atrial Fibrillation and Subsequent Use of Oral Anticoagulants in Patients with Dementia Thromb. Haemost. (IF 6.7) Pub Date : 2023-10-30 Chuan-Tsai Tsai, Yi-Hsin Chan, Jo-Nan Liao, Tzeng-Ji Chen, Gregory Y. H. Lip, Shih-Ann Chen, Tze-Fan Chao
Background Dementia and atrial fibrillation (AF) have many shared risk factors. Besides, patients with dementia are under-represented in randomized trials, and even if AF is present, oral anticoagulants (OACs) are not prescribed frequently. This study aimed to report the incidence of newly diagnosed AF in dementia patients, and the impacts of use of vitamin K antagonist (VKA; e.g., warfarin) and non-VKA
-
Reticulated Platelets: A Promising Prognosis Marker in Cardiovascular Diseases. Thromb. Haemost. (IF 6.7) Pub Date : 2023-10-31 María Asunción Esteve-Pastor,Eva Soler-Espejo,Francisco Marín
-
Sex as a Risk Factor for Atrial Fibrillation-Related Stroke Thromb. Haemost. (IF 6.7) Pub Date : 2023-10-23 Bernadette Corica, Trudie Lobban, Mellanie True Hills, Marco Proietti, Giulio Francesco Romiti
Stroke prevention is crucial for the management of patients with atrial fibrillation (AF), and several risk factors have been identified, which increase the risk of AF-related stroke. Among these factors, female sex has been repeatedly associated with AF-related stroke risk; nonetheless, trends toward lower use of oral anticoagulant in women with AF were also reported. In this clinical focus, we discuss
-
Platelet Aggregation Is Not Altered in Men with Aortic Aneurysms. Thromb. Haemost. (IF 6.7) Pub Date : 2023-10-23 Lasse M Obel,Jes S Lindholt,Axel C Diederichsen,Christian Kring,Lars M Rasmussen,Anne B Alnor,Pernille J Vinholt
-
A New Chapter Regarding Thrombosis Risk Assessment in Total Joint Replacement Patients. Thromb. Haemost. (IF 6.7) Pub Date : 2023-10-23 Joseph A Caprini,Maryanne Cronin,Nancy Dengler,Eugene Krauss
-
Differential Effects of Erythropoietin Administration and Overexpression on Venous Thrombosis in Mice Thromb. Haemost. (IF 6.7) Pub Date : 2023-10-16 Sven Stockhausen, Badr Kilani, Irene Schubert, Anna-Lena Steinsiek, Sue Chandraratne, Franziska Wendler, Luke Eivers, Marie-Luise von Brühl, Steffen Massberg, Ilka Ott, Konstantin Stark
Background Deep vein thrombosis (DVT) is a common condition associated with significant mortality due to pulmonary embolism. Despite advanced prevention and anticoagulation therapy, the incidence of venous thromboembolism remains unchanged. Individuals with elevated hematocrit and/or excessively high erythropoietin (EPO) serum levels are particularly susceptible to DVT formation. We investigated the
-
Platelet Function and Maturity and Related microRNA Expression in Whole Blood in Patients with ST-Segment Elevation Myocardial Infarction Thromb. Haemost. (IF 6.7) Pub Date : 2023-10-16 Oliver Buchhave Pedersen, Anne-Mette Hvas, Leonardo Pasalic, Steen Dalby Kristensen, Erik Lerkevang Grove, Peter H. Nissen
Background Reduced effect of antiplatelet therapy has been reported in patients with ST-segment elevation myocardial infarction (STEMI). MicroRNAs (miRs) may influence platelet function and maturity, and subsequently the effect of antiplatelet therapy. Objectives We aimed to explore the association between miR expression and platelet function and maturity in patients with acute STEMI and healthy individuals
-
Factor Xa Inhibitor Plasma Concentrations and Clinical Outcomes in Patients Weighing ≤50 kg-Experience from Four UK Centers. Thromb. Haemost. (IF 6.7) Pub Date : 2023-10-16 Victoria Speed,Rachel Clapham,John Bartoli-Abdou,Katherine Stirling,Frances Akor,Victoria Collings,Rachna Patel,Rosalind Byrne,Roopen Arya,Jignesh P Patel
-
Platelet activation is upregulated in cirrhotic patients with portal vein thrombosis. Thromb. Haemost. (IF 6.7) Pub Date : 2023-10-12 Jingnuo Ding,Fazhi Zhao,Juanjuan Cui,Mingqing Zhu,Weifeng Zhao
OBJECTIVE The alteration of platelet function plays a key role in thrombosis formation. This study aimed to explore platelet function alterations in the formation of portal vein thrombosis (PVT) in cirrhosis. METHODS Cirrhotic patients admitted to hospital between October 2021 and April 2023 were recruited and divided into PVT and non-PVT groups. Flow cytometry was used to detect the expression of
-
Effect of Previous INR Control during VKA Therapy on Subsequent DOAC Adherence and Persistence, in Patients Switched from VKA to DOAC Thromb. Haemost. (IF 6.7) Pub Date : 2023-10-09 Tessa Elling, Eelko Hak, Jens H. Bos, Vladimir Y. I. G. Tichelaar, Nic J. G. M. Veeger, Karina Meijer
Introduction Current guideline suggests a switch from vitamin K antagonist (VKA) to direct oral anticoagulant (DOAC) in patients with low time in therapeutic range (TTR < 70%). Poor international normalized ratio (INR) control may be the result of poor compliance, and might therefore be associated with subsequent DOAC intake. Therefore, this study evaluates the effect of previous TTR and other measures
-
Macrophage Ferroptosis Promotes MMP2/9 Overexpression Induced by Hemin in Hemorrhagic Plaque Thromb. Haemost. (IF 6.7) Pub Date : 2023-10-09 Bicheng Li, Minqiao Lu, Hui Wang, Siqi Sheng, Shuyuan Guo, Jia Li, Ye Tian
Background Intra-plaque hemorrhage (IPH) leads to rapid plaque progression and instability through upregulation of matrix metalloproteinases (MMPs) and collagen degradation. Hemoglobin-derived hemin during IPH promotes plaque instability. We investigated whether hemin affects MMP overexpression in macrophages and explored the underlying mechanisms. Material and Methods In vivo, hemorrhagic plaque models
-
Venous Thromboembolism and Obesity: Moving Toward a Better Understanding of the Population-Attributable Risk. Thromb. Haemost. (IF 6.7) Pub Date : 2023-10-09 Karlyn A Martin,Neil A Zakai
-
Catheter-Directed Thrombolysis for Deep Vein Thrombosis: Serving at Break Point. Thromb. Haemost. (IF 6.7) Pub Date : 2023-10-09 Geoffrey D Barnes,Andrea T Obi
-
Strategies for Tailored Antiplatelet Therapy after Percutaneous Coronary Intervention: Unraveling Complexities, Embracing Nuances. Thromb. Haemost. (IF 6.7) Pub Date : 2023-10-09 Davide Landolina,Nicola Ammirabile,Davide Capodanno
-
Phenotypes of Disseminated Intravascular Coagulation Thromb. Haemost. (IF 6.7) Pub Date : 2023-10-03 Takeshi Wada, Satoshi Gando
Two phenotypes of disseminated intravascular coagulation (DIC) are systematically reviewed. DIC is classified into thrombotic and fibrinolytic phenotypes characterized by thrombosis and hemorrhage, respectively. Major pathology of DIC with thrombotic phenotype is the activation of coagulation, insufficient anticoagulation with endothelial injury, and plasminogen activator inhibitor-1-mediated inhibition
-
The C-Type Lectin Receptor CD93 Regulates Platelet Activation and Surface Expression of the Protease Activated Receptor 4 Thromb. Haemost. (IF 6.7) Pub Date : 2023-09-30 Silvia Maria Grazia Trivigno, Mauro Vismara, Ilaria Canobbio, Serena Rustichelli, Federico Galvagni, Maurizio Orlandini, Mauro Torti, Gianni Francesco Guidetti
Background The C-type lectin receptor CD93 is a single pass type I transmembrane glycoprotein involved in inflammation, immunity, and angiogenesis. This study investigates the role of CD93 in platelet function. CD93 knockout (KO) mice and wild-type (WT) controls were compared in this study. Methods Platelet activation and aggregation were investigated by flow cytometry and light transmission aggregometry
-
Anti-thrombotic Effects Mediated by a Novel Dual-Target Peptide Inhibiting Both Platelet Aggregation and Thrombin Activity without Causing Bleeding Thromb. Haemost. (IF 6.7) Pub Date : 2023-09-25
Background Classical anticoagulants and antiplatelets are associated with high frequencies of bleeding complications or treatment failure when used as single agents. Thrombin plays an important role in the blood coagulation system. GP IIb/IIIa is the central receptor of platelets, which can recognize the Arg-Gly-Asp (RGD) sequence and activate platelets. Material and Methods Molecular simulation and
-
Neutrophil Extracellular Traps: Potential Prothrombotic State Markers and Therapeutic Targets for Atrial Fibrillation Thromb. Haemost. (IF 6.7) Pub Date : 2023-09-21
Background Recently, the mechanism of thrombogenesis has taken a new direction with the involvement of neutrophil extracellular traps (NETs). However, little is known about the relationship between NETs and thrombogenesis in atrial fibrillation (AF). Objective Our study aimed to evaluate NETs in AF patients and their potential association with thrombogenesis. In addition, we studied the effect of NETs
-
Clinical Implications of Discrepancy between One-Stage Clotting and Chromogenic Factor IX Activity in Hemophilia B Thromb. Haemost. (IF 6.7) Pub Date : 2023-09-18 David E. Schmidt, Åsa Truedsson, Annelie Strålfors, Johanne Andersen Hojbjerg, Nida Soutari, Margareta Holmström, Susanna Ranta, Anna Letelier, Annette Bowyer, Rolf Ljung, Jovan Antovic, Maria Bruzelius
Background Discrepancy in factor IX activity (FIX:C) between one-stage assay (OSA) and chromogenic substrate assay (CSA) in patients with hemophilia B (PwHB) introduces challenges for clinical management. Aim To study the differences in FIX:C using OSA and CSA in moderate and mild hemophilia B (HB), their impact on classification of severity, and correlation with genotype. Methods Single-center study
-
Plasma Soluble Glycoprotein VI: A Biomarker of Bleeding. Thromb. Haemost. (IF 6.7) Pub Date : 2023-09-18 David J Schneider
-
Kidney Disease and Cancer Risk in Patients with Venous Thromboembolism: What Does It Mean for Clinical Practice? Thromb. Haemost. (IF 6.7) Pub Date : 2023-08-11 Stavros V Konstantinides